Search alternatives:
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
rate increased » greater increase (Expand Search)
a large » _ large (Expand Search)
b large » _ large (Expand Search), i large (Expand Search), _ larger (Expand Search)
c large » _ large (Expand Search), i large (Expand Search), _ larger (Expand Search)
c rate » _ rate (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
rate increased » greater increase (Expand Search)
a large » _ large (Expand Search)
b large » _ large (Expand Search), i large (Expand Search), _ larger (Expand Search)
c large » _ large (Expand Search), i large (Expand Search), _ larger (Expand Search)
c rate » _ rate (Expand Search)
-
161
Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
162
Table1_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.DOCX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
163
Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
164
Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX
Published 2022“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
-
165
-
166
Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx
Published 2025“…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
-
167
Data Sheet 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx
Published 2025“…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
Change in smooth muscle NO from a dynamic increase in flow.
Published 2020“…<p>Simulations were performed using a static proximal model with a NO production rate in the parenchyma of 0.02 M/s corresponding to 50% GC activity with no flow. …”
-
176
Illustration of decline in network accuracy associated with large window sizes, using simulated data.
Published 2021“…<p>(a, b) Simulated articulatory signals associated with simulated /p/ and /t/ onsets. …”
-
177
-
178
Supplementary Material for: High-sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care
Published 2025“…Laboratory data, blood pressure, and anthropomorphic measures were extracted from the electronic medical record Results: Remeasurement of hsTnI did not change risk category in 92.7% of cases. Male sex, higher HDL-C, higher Hgb A1c, decreasing eGFR, and increasing systolic blood pressure were significant predictors of increased hsTnI. …”
-
179
-
180